Ascletis Pharma Inc. (2VJ.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
At close: 09:59AM CEST
| Previous Close | 0.1390 |
| Open | 0.1510 |
| Bid | 0.1510 x 0 |
| Ask | 0.1680 x 0 |
| Day's Range | 0.1500 - 0.1510 |
| 52 Week Range | 0.1290 - 0.2860 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 178.67M |
| Beta (5Y Monthly) | 0.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Ascletis Announces Strategic Decisions on FXR agonist ASC42
Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today the strategic decisions on farnesoid X receptor (FXR) agonist ASC42.
- PR Newswire
Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces the poster presentation of Phase II study final results of ASC40, a first-in-class fatty acid synthase (FASN) inhibitor for treatment of acne, at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, the United States.
- PR Newswire
Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces dosing of the first patient in Phase III clinical trial of ASC40 (Denifanstat) for treatment of moderate to severe acne vulgaris at Huashan Hospital, Fudan University.
© 2024 Yahoo. All rights reserved.